Clinical trials: Dyskinesias
SCA, Spinocerebellar Ataxias
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
- Trial name
- NCT06034886
- Testing
- Troriluzole
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Spinocerebellar Ataxia
Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.
- Trial name
- NCT06633003
- Testing
- Antrodia cinnamomea Products
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- ALPS Biotech CO. LTD
Essential Tremor
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.
- Trial name
- NCT05122650
- Testing
- JZP385
- Where
- 73 sites in United States, Germany and 2 more
- Volunteers
- 420 people
- Sponsor
- Jazz Pharmaceuticals
Huntington Disease, Tardive Dyskinesia
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
This is a A single-center, randomized, open-label, two-dose, two-period, crossover trial was conducted to evaluate the effect of food on the Pharmacokinetic characteristics and safety of oral administration of LPM3770164…
- Trial name
- NCT06474650
- Testing
- LPM3770164 sustained release tablet
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Tremor, Action Tremor
Deep Brain Stimulation (DBS) for the Suppression of Tremor
The purpose of the proposed study is to demonstrate the safety and efficacy of the ANS Totally Implantable Deep Brain Stimulation System in the VIM nucleus of the thalamus implanted for the treatment of tremor due to essential…
- Conditions
- Tremor, Action Tremor, Essential Tremor, Tremor, Limb
- Trial name
- NCT02087046
- Testing
- ANS Totally Implantable Deep Brain Stimulation System
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Abbott Medical Devices
Machado-Joseph Disease / Spinocerebellar Ataxia 3
Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease
This is an exploratory, randomized, parallel-group, dose escalation and dose-controlled study without a placebo arm. Eligible patients will be randomized in a 1:1 ratio (double-blind) to receive Cabaletta in 2 doses, once weekly…
- Trial name
- NCT02147886
- Testing
- Cabaletta for IV infusion once weekly during 24 weeks
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Bioblast Pharma Ltd.
Essential Tremor, Movement Disorders
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
The purpose of this study is to evaluate the effectiveness, safety and tolerability of carisbamate treatment for the signs, symptoms, and impairment associated with Essential Tremor (ET) compared to placebo treatment.
- Trial name
- NCT00524056
- Testing
- Carisbamate
- Volunteers
- 62 people
- Sponsor
- SK Life Science, Inc.
Alzheimer's Disease, Huntington's Disease
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects.
- Trial name
- NCT00827034
- Testing
- Warfarin, Dimebon
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Blepharospasm, Hemifacial Spasm
Post Marketing Surveillance Study of Dysport
The purpose of this study is to provide further information regarding the risks and benefits of Dysport in marketed indications.
- Conditions
- Blepharospasm, Hemifacial Spasm, Cervical Dystonia, Spasmodic Torticollis
- Trial name
- NCT00210431
- Where
- 36 sites in France, Germany and 1 more
- Volunteers
- 783 people
- Sponsor
- Ipsen
Agitation, Alzheimer's Type Dementia
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Trial name
- NCT05397639
- Testing
- Masupirdine 50 mg, Masupirdine 100 mg
- Where
- 44 sites in United States, Croatia and 2 more
- Volunteers
- 375 people
- Sponsor
- Suven Life Sciences Limited
Tremor, Essential, Neurologic Manifestations
Safety and Feasibility of ExAblate Neuro System to Perform Auto-Focusing Echo Imaging in Patients With Essential Tremor
The objective of this study is to evaluate the safety and feasibility of Auto Focusing (AF) echo imaging using the ExAblate Neuro system
- Conditions
- Tremor, Essential, Neurologic Manifestations, Tremor
- Trial name
- ET004 (NCT03935581)
- Testing
- ExAblate
- Where
- 2 sites in Canada, South Korea
- Volunteers
- 20 people
- Sponsor
- InSightec
Parkinson's Disease
Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease
The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.
- Trial name
- Fjord (NCT00559871)
- Testing
- fipamezole
- Where
- 36 sites in United States, India
- Volunteers
- 180 people
- Sponsor
- Juvantia Pharma Ltd
Huntington's Disease
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
This study will evaluate the Safety, Tolerability and Brain Function of 2 doses of PF-0254920 in Subjects with Early Huntington's Disease.
- Trial name
- NCT01806896
- Testing
- PF-02545920
- Where
- France
- Volunteers
- 37 people
- Sponsor
- Pfizer
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's…
- Conditions
- Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
- Trial name
- NCT05822908
- Testing
- VO659
- Where
- 14 sites in Denmark, France and 4 more
- Volunteers
- 68 people
- Sponsor
- Vico Therapeutics B. V.
Dyskinesias
A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia
The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.
- Trial name
- ASTORIA (NCT03956979)
- Testing
- JM-010 group A, JM-010 group B
- Where
- 5 sites in France, Germany and 3 more
- Volunteers
- 89 people
- Sponsor
- Contera Pharma
Parkinson's Disease, Essential Tremor
Movement Disorder Quantification Algorithm Development
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such…
- Trial name
- NCT01534650
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Dyskinesia, Levodopa Induced Dyskinesia
Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)
This is a multi-center, randomized, double-blind, placebo-controlled, 4-arm parallel group study to evaluate the tolerability and efficacy of each of three dose levels of ADS-5102 oral capsules, an extended release formulation of…
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia, Parkinson's Disease
- Trial name
- EASED (NCT01397422)
- Testing
- ADS-5102 (extended release amantadine HCl)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Essential Tremor
Adaptive Portable Essential Tremor Monitor
The purpose of this study is to evaluate the utility of a portable motion sensor-based system designed to monitor essential tremor (ET) to better prescribe therapy to minimize symptoms and expand care for ET patients.
- Trial name
- NCT01602042
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Huntington's Disease, Chorea
Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea
This study will assess the efficacy, safety and tolerability of AFQ056 when added to optimize standard therapy in patients that have Huntington's disease in reducing chorea.
- Trial name
- NCT01019473
- Testing
- AFQ056
- Where
- 10 sites in Germany, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)
Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
- Trial name
- NCT06069934
- Testing
- Pridopidine
- Where
- 32 sites in United States, Puerto Rico
- Sponsor
- Prilenia